Adding bevacizumab, temsirolimus, or ixabepilone to paclitaxel and carboplatin (PC) does not improve survival outcomes among patients with advanced/recurrent endometrial cancer compared with PC alone, according to a study published in Gynecologic Oncology.
PC is one of the standards of care for endometrial cancer. Bevacizumab, ixabepilone, and temsirolimus have demonstrated potential activity in previous studies; researchers sought to determine the efficacy and tolerability of adding any of these novel agents to standard therapy.
In this phase 2 study, researchers randomly assigned 349 chemotherapy-naïve patients with advanced or recurrent endometrial cancer to receive PC plus bevacizumab (Arm 1), PC plus temsirolimus (Arm 2), or ixabepilone and carboplatin plus bevacizumab (Arm 3). Patients underwent a computed tomography (CT) scan within the first 4 weeks of treatment and was repeated every 9 weeks for 2 years, then every 3 months until disease progression.
Results showed that progression-free survival (PFS) did not improve significantly in any study arm compared with historical controls (P >.039). Response rates were similar in all study arms; 60% in Arm 1, 55% in Arm 2, and 53% in Arm 3.
Compared with controls, the overall survival duration was significantly prolonged in Arm 1, but not in Arms 2 and 3.
The toxicity profile was similar to those previously reported.
Aghajanian C, Filiaci V, Dizon DS, et al. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer [published online May 24, 2018]. Gynecol Oncol. doi: 10.1016/j.ygyno.2018.05.018